Natriuresis-Guided Diuretic Therapy in Acute Heart Failure (PUSH-AHF)

Authors, Journal, Affiliations, Type, DOI

Overview

PUSH-AHF asked whether titrating intravenous loop diuretics to measured urinary sodium improves decongestion in acute heart failure. In 310 patients at one Dutch centre, a protocol that measured spot urinary sodium at 2, 6, 12, 18, 24 and 36 hours and escalated treatment when it fell below 70 mmol/L raised 24-hour natriuresis from 345 to 409 mmol (P=0.0061) — meeting the first of its dual primary endpoints — and roughly doubled the cumulative in-hospital loop diuretic dose without any excess of renal events. It did not reduce the second primary endpoint of death or heart-failure rehospitalisation at 180 days (31% vs 31%; HR 0.92), and the trial was powered only to detect a hazard ratio of 0.49, with a lower event rate than anticipated. The result is therefore a proof of concept for urine sodium as a treatment target, on a surrogate, in a population in which the clinical endpoint was never realistically testable at this size.

Keywords

Acute heart failure, decompensated heart failure, loop diuretics, bumetanide, natriuresis, spot urinary sodium, diuretic resistance, decongestion, sequential nephron blockade, hydrochlorothiazide, acetazolamide, pragmatic trial

Key Takeaways

Background and Rationale

Trial Design

Population

Decongestive Treatment Delivered

Primary End Points

End point Natriuresis-guided Standard of care Effect (95% CI) P
24-hour natriuresis — mmol 409±178 345±202 difference 63 (18–109) 0.0061
Death or HF rehospitalisation at 180 days 46/150 (31%) 50/159 (31%) HR 0.92 (0.62–1.38) 0.6980

Secondary End Points

End point Natriuresis-guided Standard of care Effect (95% CI) P
48-hour natriuresis — mmol 653±249 575±290 78 (10–145) 0.0241
24-hour diuresis — ml 3,900 (3,200–4,945) 3,330 (2,510–4,500) 534 (160–908) 0.0053
48-hour diuresis — ml 6,655 (5,401–7,824) 5,915 (4,600–7,400) 672 (137–1,206) 0.0140
Length of hospital stay — days 6 (5–9) 7 (5–10) — 0.1436
HF rehospitalisation — % 17 17 HR 0.96 (0.56–1.67) 0.8904
180-day all-cause mortality — % 19 21 HR 0.89 (0.54–1.46) 0.6369
NT-proBNP change at 48 h — % −22 −18 — 0.4351
NT-proBNP change at 72 h — % −33 −33 — 0.7881

Safety

Interpretation

Limitations of the document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated